Loading…
ENVB
Enveric Biosciences, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 29405E505
$1.370.00%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $6.13M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$12.18
- ROE
- -170.04%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.11
- 52-week high
- $13.63
- 52-week low
- $1.17
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.01▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.63 | $966.60 | $3,510.00 | $5,616.00 | |
| P/B | 190.3x | 0.9x | 411.4x | 327.7x | 53.0x |
| EPS | -$36.24 | -$228.48 | -$1,455.48 | -$195.00 | |
| ROE | -405.56% | -209.98% | -601.14% | -884.86% | -126.12% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ACXPAcurx Pharmaceuticals, Inc. | $1.44 | — | 0.8x | — | -128.11% | $6.19M |
| XTLBXtl Biopharmaceuticals Ltd | $2.47 | — | — | — | -29.30% | $6.07M |
| SNOASonoma Pharmaceuticals, Inc. | $1.31 | — | 0.8x | — | -42.52% | $6.27M |
| HCWBHCW Biologics Inc. | $3.43 |
About the company
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
- 5
- Cambridge, United States
Company description provided by Yahoo Finance.